Former Vols, Bucs Defensive Lineman Steve White Dies at 48 He was diagnosed with chronic lymphocytic leukemia in 2014 and shared in April that he needed to undergo a bone marrow transplant. Sports Illustrated · Aug 31, 2022
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular… Benzinga · Aug 30, 2022
Italian Dad And Japanese Mom Need Special Donor For Child, 2, With Leukemia The Italian dad and Japanese mom of a two-year-old with a rare kind of leukemia have launched a crowdfunding campaign to find a special donor matching their child’s genetic makeup. Zenger · Aug 30, 2022
Recap Of Friday's Biotech Catalysts - End Of the Day Summary The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25… Benzinga · Aug 26, 2022
Recap Of Monday's Biotech Catalysts - End Of the Day Summary The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares… Benzinga · Aug 22, 2022
Camp Lejeune’s water poisoned lives. Decades of fighting finally caused change Jerry Ensminger sat in the balcony of the U.S. Senate chamber watching a vote that had begun to feel like a pipe dream. McClatchy Washington Bureau · Aug 10, 2022
Modified Cell Immune Response Key To Defeating Lymphoma, Leukemia Scientifically-altered T cells, which produce the body’s immune response, may be a key to defeating leukemia, lymphoma, and multiple myeloma, say authors of a new study. Zenger · Aug 3, 2022
Recap Of Monday's Biotech Catalysts - End Of the Day Summary The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand… Benzinga · Aug 1, 2022
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy Here's a roundup of top developments in the biotech space over the last 24 hours: Benzinga · Jul 27, 2022
ISC results: Lucknow girl combats cancer to score 97.75% LUCKNOW: After 17-year-old Pramita Tewari was diagnosed with Acute Minor Leukemia last year in August, many thought that her future was bleak, but this gritty young girl put up a brave fight. Not only is she on the path of recovery, but also kept her studies going from hospital. The Times of India · Jul 25, 2022
Houston Texans rookie John Metchie III diagnosed with leukemia John Metchie III, the Houston Texans’ 22-year-old wide receiver, has been diagnosed with leukemia and expects to miss the upcoming season, he announced Sunday. Tribune News Service · Jul 25, 2022
Saban Releases Statement Following Metchie III Leukemia Diagnosis The Texans rookie receiver starred at Alabama from 2019 to ’21. Sports Illustrated · Jul 24, 2022
Understanding Texans WR John Metchie’s Acute Promyelocytic Leukemia diagnosis Houston Texans WR John Metchie was diagnosed with Acute Promyelocytic Leukemia, which can be a treatable form of cancer. USA Today Sports Media Group · Jul 24, 2022
Texans show support for WR John Metchie following Acute Promyelocytic Leukemia diagnosis Receiver John Metchie drew support from past and present Houston Texans following his announcement of his Acute Promyelocytic Leukemia diagnosis. USA Today Sports Media Group · Jul 24, 2022
USA Today Sports Media Group · Jul 24, 2022 Twitter reacts to Leukemia diagnosis of Texans rookie WR John Metchie Houston Texans rookie receiver John Metchie gathered an outpouring of support on Twitter following his diagnosis of Acute Promyelocytic Leukemia.
USA Today Sports Media Group · Jul 24, 2022 Texans rookie WR John Metchie III announces leukemia diagnosis Houston Texans second-round pick John Metchie III has been diagnosed with acute promyelocytic leukemia
Sports Illustrated · Jul 24, 2022 Texans Rookie John Metchie III Announces Leukemia Diagnosis The Houston wide receiver is expected to miss the 2022 season.
USA Today Sports Media Group · Jul 24, 2022 Texans rookie WR John Metchie diagnosed with Acute Promyelocytic Leukemia and likely to miss 2022 season Houston Texans rookie receiver John Metchie announced his Acute Promyelocytic Leukemia diagnosis, and says he may miss the 2022 season.
USA Today Sports Media Group · Jul 24, 2022 John Metchie III diagnosed with Leukemia Houston Texans rookie wide receiver John Metchie III announced he was diagnosed with a form of Leukemia.
Benzinga · Jul 22, 2022 Recap Of Friday's Biotech Catalysts - End Of The Day Summary Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…
Belfast Live · Jul 18, 2022 Ballymena boy diagnosed with leukemia after limping for weeks "This has to be any parent's worst nightmare"
Sports Illustrated · Jul 14, 2022 Ducks Prospect Finished 2 1/2 Years of Leukemia Treatments The 22-year-old rang the bell on Monday to officially signal the end of two-and-a-half years of chemo treatments.
Dublin Live · Jul 14, 2022 Stephen Bradley shaves his head for young son's charity fundraiser His son Josh was diagnosed with Acute lymphocytic leukemia last month and the family have started a 'Shave your head' fundraising challenge
Zenger · Jul 6, 2022 Deadly Genetics: Gene Mutations May Be Source Of Deadly Blood Cancer "Identifying a future risk of development of leukemia may ultimately offer the possibility of prevention."
Benzinga · Jul 5, 2022 Why Precigen Shares Are Gaining Today Precigen Inc (NASDAQ:PGEN) has agreed to sell its subsidiary Trans Ova Genetics, an animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership. The deal consideration includes $170 million in upfront cash and up to $10 million earn-out based on the performance of Trans Ova in 2022 and 2023. …